Watchlist
SENS · Senseonics Holdings, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Resolved Graded and closed 2026-08-07 at low conviction — the published kill line did not fire. Coverage continued after the close; the read below is dated 2026-09-13 and is not part of the scored record.
Current thesis
Only year-long implantable CGM, clinically de-risked at ADA 2026 with revenue +71.9% YoY TTM — and the tape has spent six weeks grinding back toward the $4.79 post-catalyst low ($5.11 on Jul 17). Accelerating fundamentals against a broken price structure; the Aug 5 Q2 print, with cash burn and dilution the swing factor, is the next real test.
Kill line
A weekly close below $4.79 breaks the June post-ADA low and confirms the dilution-spiral leg lower; a secondary confirmation would be the Aug 5 Q2 print showing burn accelerating with no breakeven path. An upside flip requires reclaiming and holding the 50-day on expanding volume.
Pick status
Played out resolved published kill line did not fire How this is scored →Latest analysis and events for SENS —
As of 13 September 2026, the latest FrontierPicks analysis for Senseonics Holdings, Inc. (SENS): Only year-long implantable CGM, clinically de-risked at ADA 2026 with revenue +71.9% YoY TTM — and the tape has spent six weeks grinding back toward the $4.79 post-catalyst low ($5.11 on Jul 17). Accelerating fundamentals against a broken price structure; the Aug 5 Q2 print, with cash burn and dilution the swing factor, is the next real test.
Kill line: A weekly close below $4.79 breaks the June post-ADA low and confirms the dilution-spiral leg lower; a secondary confirmation would be the Aug 5 Q2 print showing burn accelerating with no breakeven path. An upside flip requires reclaiming and holding the 50-day on expanding volume.
Most recent dated event on file: — catalyst 6d ago.
Current Thesis
Senseonics' implantable glucose-monitor growth story needs Q3 sales confirmation and recovery of the September price shelf; a weekly close below $7.81 would invalidate the recovery thesis. Confirmation means Q3 US revenue exceeding the $12.6 million reported for Q2 2026, unchanged or higher annual revenue guidance, and a weekly close above the September 2 reference close of $9.94.
The September 3 consolidation thesis has weakened: the adjusted daily close was $8.71 on September 11, below the August 21 close of $9.71 and September 2 close of $9.94. The narrative is maturing — an inference from that retreat and the 14-period relative strength index (RSI) falling from 76.5 on September 2 to 33.1 on September 11. These observations establish weaker momentum, not the identity of sellers.
The calendar has changed. Senseonics announced on September 10 that management would present at the H.C. Wainwright conference on September 14. That replaces an empty company-event calendar with a dated management appearance; the announcement contains no new financial results. Company announcement.
Bullish and bearish views on Senseonics Holdings, Inc.
The model's bull view on Senseonics Holdings, Inc. (SENS), in brief: Commercial growth remains measurable. Senseonics reported Q2 2026 revenue of $14.5 million and US revenue of $12.6 million, up more than 150% year over year, on August 6. Q2 results. Margin guidance moved higher. On August 6, management raised its 2026 revenue outlook to $62–66… The bear view: September support has failed. The September 11 close of $8.71 is below both reference closes defining the previously discussed $9.71–$9.94 congestion. The price record no longer supports describing that upper area as holding support. Commercial expansion carries costs. Q2 2026… Both cases follow in full.
Bull Case
- Commercial growth remains measurable. Senseonics reported Q2 2026 revenue of $14.5 million and US revenue of $12.6 million, up more than 150% year over year, on August 6. Q2 results.
- Margin guidance moved higher. On August 6, management raised its 2026 revenue outlook to $62–66 million and gross-margin outlook to 58–61%. These are management forecasts; subsequent guidance cuts would contradict the operating case. Q2 results.
- The earlier advance remains visible. The September 11 adjusted close of $8.71 remains above the August 14 reference close of $7.81. The supplied adjusted series records a three-month price increase of 21.3% through September 11, despite the recent retreat.
Bear Case
- September support has failed. The September 11 close of $8.71 is below both reference closes defining the previously discussed $9.71–$9.94 congestion. The price record no longer supports describing that upper area as holding support.
- Commercial expansion carries costs. Q2 2026 net loss was $36.7 million, according to the August 6 release. Revenue growth has not established profitability. Q2 results.
- Equity financing is documented. The May 4 closing announcement records approximately $92 million in gross offering proceeds, including full exercise of the underwriters' option. This updates the earlier $80 million pricing description; it does not establish issuance during September's pullback. Offering completion.
Setup & Price Structure
The September 11 adjusted close was $8.71, with RSI at 33.1 and the shares 22.9% below the supplied 52-week high of $11.30. No current moving-average value or slope is available, so distance above a rising average cannot be assessed.
The August 14 close of $7.81 provides a dated reference for invalidation, rather than proof of repeatedly tested support. The August 21 and September 2 closes define the overhead $9.71–$9.94 recovery zone. A weekly close above $9.94 would satisfy the price component of confirmation; a weekly close below $7.81 would end this recovery case.
Crowding remains unmeasured. The August 14 Benzinga Cramer roundup mentioned Senseonics' sales, but the available coverage sample is too small to establish retail-attention clustering. September turnover, short interest and verified insider-sale details are missing; RSI cannot substitute for those observations.
Catalyst Calendar (next 30 days)
- 2026-09-28 through 2026-10-02: The European Association for the Study of Diabetes annual meeting takes place in Milan. The reviewed Senseonics announcement does not establish a company presentation there, so the meeting is an industry calendar event, not a confirmed company data release. Meeting dates.
- ~2026-11-05, est.: Q3 2026 results remain the decisive operating checkpoint beyond this window. This is the previously published estimate; the company release index reviewed September 13 contains no Q3 earnings-date announcement. The test is sequential US sales growth and preservation of annual guidance. Company release index.
Elapsed catalysts
- 2026-09-14: Management is scheduled to present at the H.C. Wainwright conference at 3:00 p.m. Eastern Time, as announced September 10. This is a company-confirmed communication event; an appearance without new operating disclosure leaves Q3 confirmation outstanding. Company announcement. (passed 6d ago)
What Would Change Our Mind
Loss of the remaining August reference would break the recovery structure: a weekly close below $7.81 invalidates the thesis. This threshold uses the August 14 adjusted close and supersedes the much older June reference for the current commercial-recovery case.
Operating confirmation requires Q3 US revenue above Q2's $12.6 million and maintenance or improvement of the August 6 annual revenue outlook. US revenue at or below that comparator, or a guidance cut, would contradict the continuation case even if the price threshold remained intact.
Correlation Notes
This is a single-name commercialization thesis. Senseonics' August 6 release attributes commercial changes to bringing distribution in-house; that company-specific transition limits what a broader medical-device rally could establish about demand. Q2 results. No synchronized peer or index return series accompanies the September 11 observations, so no measured correlation or sector-flow conclusion is supported.
Notes
- Serial issuer: $80M offering priced 2026-05-01 at $5.00/sh (8.0M shares + 8.0M pre-funded warrants) off shelf File No. 333-289306, which remains available.
- Single-product concentration: $12.6M of $14.5M Q2 2026 revenue is US Eversense 365, so coverage, pricing or competitive shocks land on the entire P&L.
- Split-stale aggregator data: some services still carry pre-consolidation SENS figures, including a syndicated H.C. Wainwright target quoted as '$1.40 from $1.10'.
- Analyst targets are inconsistent across aggregators; stockanalysis.com shows $13.40 average across 7 analysts, while other services show a $14.00 median with an $8.00-$18.00 spread.
- Gemini self-powered next-gen sensor: pivotal trial completion guided to H2 2026, commercial launch targeted 2027, with no specific date announced.
- 2021 meme-era shareholder lineage plus 52.87M shares outstanding means retail flow velocity can dominate the price for days regardless of company disclosure.
Related · shared themes
TXG
10x Genomics, Inc.
10x Genomics' Atera recovery now needs deliveries and revenue confirmation after clearing its earlier price hurdle. Approximately 40 second-half 2026 shipments and full-year revenue of $610–630 million would substantiate the case before a weekly close below $58.57 invalidates the structure.
ITGR
Integer Holdings Corporation
Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it.
PSNL
Personalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.
VREX
Varex Imaging Corporation
Varex Imaging Corporation’s $18.90 cash acquisition by Teledyne remains a completion thesis. The 2026-09-08 preliminary proxy advances the process; payment resolves the case, while a daily close below $17.50 invalidates it.
See also · stocks to watch